Photocure (LSE:0IMT) - Stock Price, News & Analysis

0IMT Stock Overview

Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details

0IMT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 87% below our estimate of its fair value

Earnings are forecast to grow 94.94% per year

Became profitable this year

Risk Analysis

No risks detected for 0IMT from our risk checks.

Photocure ASA Competitors

Animalcare Group

AIM:ANCR

UK£148.5m

ECO Animal Health Group

AIM:EAH

UK£43.4m

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

hVIVO

AIM:HVO

UK£136.1m

Price History & Performance

Summary of all time highs, changes and price drops for Photocure
Historical stock prices
Current Share Price	NOK 51.50
52 Week High	NOK 71.90
52 Week Low	NOK 48.05
Beta	0.99
11 Month Change	-2.83%
3 Month Change	3.00%
1 Year Change	2.80%
33 Year Change	-46.52%
5 Year Change	-40.22%
Change since IPO	13.19%

Recent updates

Shareholder Returns

	0IMT	GB Pharmaceuticals	GB Market
7D	-1.5%	5.0%	2.2%
1Y	2.8%	2.5%	8.8%

Return vs Industry: 0IMT matched the UK Pharmaceuticals industry which returned 2.2% over the past year.

Return vs Market: 0IMT underperformed the UK Market which returned 8.3% over the past year.

Price Volatility

Is 0IMT's price volatile compared to industry and market?
0IMT volatility
0IMT Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0IMT has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0IMT's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1993	102	Dan Schneider	www.photocure.com

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.

Photocure ASA Fundamentals Summary

How do Photocure's earnings and revenue compare to its market cap?
0IMT fundamental statistics
Market cap	NOK 1.31b
Earnings (TTM)	NOK 14.16m
Revenue (TTM)	NOK 526.25m

92.6x

P/E Ratio

2.5x

P/S Ratio

Is 0IMT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0IMT income statement (TTM)
Revenue	NOK 526.25m
Cost of Revenue	NOK 29.11m
Gross Profit	NOK 497.15m
Other Expenses	NOK 482.98m
Earnings	NOK 14.16m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.52
Gross Margin	94.47%
Net Profit Margin	2.69%
Debt/Equity Ratio	0%

How did 0IMT perform over the long term?

See historical performance and comparison

0IMT Stock Overview

Rewards

Risk Analysis

Photocure ASA Competitors

AIM:ANCR

UK£148.5m

AIM:EAH

UK£43.4m

LSE:HIK

UK£4.4b

AIM:HVO

UK£136.1m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Recent updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Full year 2023 earnings released: EPS: kr0.01 (vs kr2.66 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.68 loss in 2Q 2022)

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

First quarter 2022 earnings released: kr0.82 loss per share (vs kr0.57 profit in 1Q 2021)

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) announces an Equity Buyback for 2,682,006 shares, representing 10% of its issued share capital.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Shareholder Returns

Price Volatility

About the Company